CB Insights
Technology Market Intelligence
Technology Market Intelligence
Mind-NRG is devoted to the development of NRG-101 in psychiatric and neurologic diseases. NRG-101 is a neurotrophic factor with disease modifying potential that naturally crosses the blood-brain barrier through a receptor-mediated transport to reach...Show all
Company (Alive / Active)
Phone: +41 22 737 00 00
Rue de Jargonnant 2
Geneva, CH-1207
Switzerland
| Per Week | Per Month | Per 6 Months | Per Year | |
|---|---|---|---|---|
| Rank | Login to see details | |||
| Page Views Per Million | Login to see details | |||
| Page Views Per User | Login to see details | |||
| Reach Per Million | Login to see details | |||
| Investor | Investor Type | Location | Participating Rounds |
|---|
| Name | Firm |
|---|---|
| Login to see details | Medicxi Ventures |
| Title | Application Date | Patent Date | Status (Patent / Application) |
|---|---|---|---|
| Method of effecting neuroprotection using soluble neuregulin isoforms | May 23, 2019 | Oct 27, 2020 | Patent |
| Method of effecting neuroprotection using soluble neuregulin isoforms | Oct 25, 2016 | Jul 16, 2019 | Patent |
| Use of neuregulin-ß as an indicator and/or target | Feb 25, 2011 | Oct 01, 2013 | Patent |
| Method of effecting neuroprotection using soluble neuregulin isoforms | Sep 04, 2020 | Application | |
| Active soluble post-translationally modified neuregulin isoforms | Dec 08, 2014 | Application |
